Dianthus Therapeutics Stock Rises After Roth/MKM Initiates Bullish Coverage

Dianthus Therapeutics (DNTH) shares edged higher in after-hours trading after Roth/MKM initiated coverage on the stock with a 'Buy' rating and a $113 price target. The move reinforces a broad and growing conviction among analysts regarding the clinical-stage biotechnology company's drug pipeline.

Unanimous Analyst Support

The initiation from Roth/MKM was the immediate catalyst for the stock's move, which rose 0.8% to $80 in extended trading, according to Investing.com. This new rating brings the total number of analysts covering Dianthus to 18, all of whom maintain a 'Buy' or equivalent rating, with no 'Hold' or 'Sell' ratings on record.

This strong consensus underscores Wall Street's positive outlook on the company's prospects. Other bullish price targets from analysts include:

• $158 from H.C. Wainwright
• $156 from Citi
• $135 from JPMorgan, which initiated with an 'Overweight' rating in September

Ad

Sentiment was also supported by a reiterated 'Buy' rating from Wells Fargo on October 18, keeping investor focus on the company's progress.

Pipeline and Catalysts in Focus

Analyst optimism is centered on Dianthus's complement therapeutics pipeline, particularly its claseprubart program. Investors are closely watching for multiple late-stage trial readouts on the horizon, which could serve as significant catalysts for the stock.

Attention is also elevated ahead of the company's next earnings report, which is scheduled for November 5. While the broader market provided a modestly supportive backdrop, the stock's movement was primarily driven by this company-specific news, with the macro environment not serving as a significant factor.